China Securities Co., Ltd. issued a research report stating that Remegen (09995) continued to increase its sales of core products in the first half of the year, achieving a good year-on-year revenue growth of 0.742 billion yuan. The company's core products, Taiptecy and Vedolizumab, cover self-immunity and tumor fields. The clinical research and commercialization of these two products are steadily progressing. In terms of innovative pipeline, the latest ovarian cancer research results of RC88 were announced at ASCO conference, showing excellent product efficacy and promising future. Overall, the bank is bullish on the company's commercial development and the subsequent clinical advancement of innovative drugs.
The bank pointed out that the company has established and improved three core innovative technology platforms, with strong independent research and development capabilities. Taiptecy and Vedolizumab are expected to continue expanding their indications, and the company's commercialization capabilities have been validated. At the same time, the company has embarked on internationalization, reaching a partnership with SEAGEN on the overseas rights of RC48, and RC18 is actively advancing clinical trials. The overall operation has become more mature and stable. The bank predicts that the company's revenue for 2024-2026 will be 1.55 billion yuan, 2.453 billion yuan, and 3.173 billion yuan, respectively, and maintains a "buy" rating.
